ESMO 2025 | What is the rationale behind targeting IL-2 activation in solid tumors?
Martina Imbimbo, MD, Ente Ospedaliero Cantonale, Lugano, Switzerland, comments on the importance of targeting interleukin-2 (IL-2) activation, particularly those that have seen an antigen and express PD-1, to avoid exhaustion in solid tumors. IL-2 agonists are biased toward the beta-gamma receptor, allowing for the preferential expansion of T-cells while minimizing the impact on regulatory T cells (Tregs) and endothelial cells, which reduces counter effects on the immune system and toxicities. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so this is an important question because we know that cells that have seen an antigen, they get exhausted, they start to express PD-1. In this way, we are going really to target the interleukin-2 activation to those cells that we really want to target. So another important thing about this product is that the IL-2 agonist is biased toward the beta-gamma receptor...
Yeah, so this is an important question because we know that cells that have seen an antigen, they get exhausted, they start to express PD-1. In this way, we are going really to target the interleukin-2 activation to those cells that we really want to target. So another important thing about this product is that the IL-2 agonist is biased toward the beta-gamma receptor. So in this way, we are trying to expand preferentially T-cells while avoiding Tregs and endothelial cells, thus reducing the counter effect on the immune system and also toxicities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
